Skip to main content

Table 2 Serum analysis

From: Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis – a prospective cohort study

Analysis All (n = 121) Responders (n = 73) Non-responders (n = 48) P-value
s-TNF (pg/mL) 0 (0 to 1,212) 0 (0 to 1,212) 0 (0 to 99) 0.399
s-IL6 (pg/mL) 14 (0 to 324) 30 (0 to 24) 7 (0 to 324) 0.629
s-VEGF (pg/mL) 218 (0 to 1,750) 218 (0 to 1,188) 212 (0 to 1,750) 0.850
s-MMP3 (pg/mL) 138 (16 to 116,714) 138 (16 to 116,714) 140 (34 to 52,031) 0.911
s-COMP (U/L) 10.7 ± 3.4 10.8 ± 3.9 10.5 ± 2.5 0.636
s–anti-CCP (>7 IU/ml) 87/121 (72%) 48/73 (66%) 39/48 (81%) 0.064
s-IgM-RF (>5 IU/ml) 90/121 (74%) 51/73 (70%) 39/48 (81%) 0.160
s-ANA 38/99 (38%) 14/39 (36%) 24/60 (33%) 0.682
  1. Median (range), mean ± SD. ANA, antinuclear antibodies; anti-CCP, anti-cyclic citrullinated peptide; COMP, cartilage oligomeric matrix protein; IgM, immunoglobulin M; MMP3, matrix metalloproteinase 3; RF, rheumatoid factor; s, serum; VEGF, vascular endothelial growth factor.